Cleveland BioLabs Receives Notice of Patent Allowance From Japan for CBLB502

Cleveland BioLabs, Inc. CBLI announced today that it has received a Notice of Allowance from the Japan Patent Office for a CBLB502 patent application. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, stated, "This Notice of Allowance expands validation of our claims regarding protection from radiation with CBLB502 and other flagellin derivatives in major jurisdictions worldwide including the United States, Europe, Eurasia, China, and now Japan. We remain focused on advancing CBLB502 towards a biologic license application with the FDA."